search
Back to results

Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis

Primary Purpose

Seasonal Allergic Rhinitis

Status
Unknown status
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
Bifidobacteria
placebo
Sponsored by
University of Campania "Luigi Vanvitelli"
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Seasonal Allergic Rhinitis

Eligibility Criteria

4 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children of both sexes , aged from 4 to 17 years
  • History seasonal allergic rhinitis mild , moderate or severe , according to the guidelines defined AIR 2013 , documented by recurrent episodes in the previous year and confirmed by skin prick test positive
  • Written informed consent of one parent or a legal representative

Exclusion Criteria:

  • Lack of written informed consent by at least one parent or a legal representative
  • Concurrent disorders such as infection of the upper or lower respiratory tract , nasal surgery in the past year , respiratory tract abnormalities , immune diseases
  • Use of antihistamines , nasal or systemic corticosteroids , leukotriene modifiers , or cromolyn sodium , on an ongoing basis used in the last six weeks.

Sites / Locations

  • Second UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Bifidobacteria mixture 0.5 ml

placebo

Arm Description

Bifidobacteria 0.5 ml per os all days for 2 months

Placebo 0.5 ml per os all days for 2 months

Outcomes

Primary Outcome Measures

Evaluation of the symptoms by structural questionary

Secondary Outcome Measures

Full Information

First Posted
June 10, 2016
Last Updated
June 25, 2018
Sponsor
University of Campania "Luigi Vanvitelli"
search

1. Study Identification

Unique Protocol Identification Number
NCT02807064
Brief Title
Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis
Official Title
Evaluation of the Effectiveness of Treatment With Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 2016 (Actual)
Primary Completion Date
July 2018 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Campania "Luigi Vanvitelli"

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is aimed at assessing the efficacy of supplementation with a mixture of three bifidobacteria , on the allergic rhinitis..The rhinitis symptoms were assessed by validated score ( TSS ) , for children aged between 4 and 17 years with allergic rhinitis parietaria , mild , moderate or severe , than children not supplemented . Secondary Objectives The effectiveness of treatment by VAS : Evaluation of the rescue medication consumption Evaluation of quality of life ( using structured questionnaire ) Evaluation of the frequency and school performance ( using structured questionnaire ) Assessment of sleep quality and attention (through structured questionnaire ) Satisfaction rating and satisfaction of parents Evaluation of asthma exacerbations in children susceptible
Detailed Description
This is a randomized , double-blind , placebo - controlled , phase 3 , 2 arms , in which patients were selected to receive placebo or a mixture powder composed of three bifidobacteria : Bifidobacterium Longum BB536 ( 3 billion units ) + Bifidobacterium infantis M - 63 ( 1 billion units ) Bifidobacterium breve M + -16 V ( 1 billion units ) . The subjects included in our study are represented by children aged between 4 and 17 years , with seasonal allergic rhinitis moderate and presenting positive skin prick test against parietaria.The participation of each subject in the study was based on evaluation of its clinical history. The recruited patients were divided into two groups according to the drug used.The group A received placebo , while the group B mixture bifidobacteria. The treatment was performed for a period of two months. At the beginning and at the end of therapy several surveys have been carried out , so as to be able to compare results and to draw some preliminary conclusions about the effectiveness of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seasonal Allergic Rhinitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bifidobacteria mixture 0.5 ml
Arm Type
Active Comparator
Arm Description
Bifidobacteria 0.5 ml per os all days for 2 months
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Placebo 0.5 ml per os all days for 2 months
Intervention Type
Drug
Intervention Name(s)
Bifidobacteria
Other Intervention Name(s)
longum infantis M16V
Intervention Description
0.5 ml per os all days for 2 months
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
0,5 ml per os all days for 2 months
Primary Outcome Measure Information:
Title
Evaluation of the symptoms by structural questionary
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children of both sexes , aged from 4 to 17 years History seasonal allergic rhinitis mild , moderate or severe , according to the guidelines defined AIR 2013 , documented by recurrent episodes in the previous year and confirmed by skin prick test positive Written informed consent of one parent or a legal representative Exclusion Criteria: Lack of written informed consent by at least one parent or a legal representative Concurrent disorders such as infection of the upper or lower respiratory tract , nasal surgery in the past year , respiratory tract abnormalities , immune diseases Use of antihistamines , nasal or systemic corticosteroids , leukotriene modifiers , or cromolyn sodium , on an ongoing basis used in the last six weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michele MD Miraglia del Giudice, Prof
Phone
+39.81.5665922
Email
michele.miragliadelgiudice@unina2.it
Facility Information:
Facility Name
Second University
City
Naples
ZIP/Postal Code
80138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele MD Miraglia del Giudice, Prof
Phone
+39.815665922
Email
michele.miragliadelgiudice@unina2.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28270216
Citation
Miraglia Del Giudice M, Indolfi C, Capasso M, Maiello N, Decimo F, Ciprandi G. Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma. Ital J Pediatr. 2017 Mar 7;43(1):25. doi: 10.1186/s13052-017-0340-5.
Results Reference
derived

Learn more about this trial

Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis

We'll reach out to this number within 24 hrs